1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NCI SBIR/STTR Omnibus Grant Solicitations is sponsored by National Cancer Institute (NCI), National Institutes of Health (NIH). The NCI SBIR/STTR program provides non-dilutive funding and commercialization support to small businesses developing innovative cancer-related technologies, including immunotherapies. It accelerates the translation of innovative immunotherapy discoveries into clinical applications.
The program supports a broad spectrum of technology readiness, from proof-of-concept studies to clinical trials.
Get alerted about grants like this
Get emailed when new opportunities from “National Cancer Institute (NCI), National Institutes of Health (NIH)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NCI SBIR/STTR Omnibus Grant Solicitations - NCI The SBIR and STTR programs were reauthorized on April 13, 2026. Currently, NIH has no active SBIR or STTR Notices of Funding Opportunity (NOFOs). Future NOFOs are forecasted at Grants.
gov prior to opening for applications. The next standard receipt date is September 5, 2026. NCI SBIR/STTR Omnibus Grant Solicitations The Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) Omnibus Solicitations are intended to support small business innovation research across a broad spectrum of topic areas.
U.S. small businesses that have the research capabilities and technological expertise to contribute to the research and development missions of the awarding components identified in the Omnibus Solicitation are encouraged to submit investigator-initiated SBIR & STTR grant applications in response to the identified topics.
Applicants may also consider other areas of research within the mission of any of the awarding components and submit an SBIR & STTR application Small business concerns that are majority-owned by multiple venture capital operating companies (VCOCs), hedge funds and/or private equity firms continue to be eligible to apply to the CDC and NIH SBIR program and compete for up to 15% and 25% respectively of each agency's SBIR set-aside.
Omnibus Solicitation Opportunities This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.
SBIR Program: PA-24-245 (Clinical Trial Not Allowed) PHS 2024-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) Standard Receipt Dates: September 5, 2024; January 5, 2025; April 5, 2025; September 5, 2025 SBIR Program: PA-24-246: (Clinical Trial Required) PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44]) Standard Receipt Dates: September 5, 2024; January 5, 2025; April 5, 2025; September 5, 2025 STTR Program: PA-24-247 (Clinical Trial Not Allowed) PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]) Standard Receipt Dates: September 5, 2024; January 5, 2025; April 5, 2025; September 5, 2025 STTR Program: PA-24-248 (Clinical Trial Required) PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]) Standard Receipt Dates: September 5, 2024; January 5, 2025; April 5, 2025; September 5, 2025 Online HTML Application Guide SF424 (R&R) Application Guide for SBIR/STTR Grant Applications (Version H) Annotated SF424 SBIR/STTR Form Set NIH Matchmaker - Use NIH Matchmaker to conduct keyword searches on a particular topic area to identify NIH Institutes or Centers (ICs) that have previously funded research area.
According to the current listing, eligibility includes: Small businesses with an investigator-defined scope within the mission of NIH, focusing on research areas such as therapeutics, diagnostics, imaging technologies, and devices for cancer therapy. Confirm the full requirements in the official notice before applying.
The current listing shows $300,000 to $4.5 million. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for NCI SBIR/STTR Omnibus Grant Solicitations are due September 5, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
NCI SBIR/STTR Omnibus Grant Solicitations is funded by National Cancer Institute (NCI), National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (SCH) is sponsored by National Science Foundation (NSF) & National Institutes of Health (NIH). This interagency program supports high-risk, high-reward interdisciplinary projects that leverage AI, machine learning, and advanced data science to address pressing questions in biomedical and public health research. It seeks to advance fundamental scientific and engineering contributions across disciplines to solve key health problems.
As of October 1, 2025, NIH no longer posts Notices of Funding Opportunity in the NIH Guide — Grants.gov is now the single official source (NOT-OD-25-143). The weekly Guide table-of-contents email that thousands of investigators relied on to discover funding no longer lists opportunities. Combined with the January 25, 2026 SciENcv certified-PDF requirement, the mechanics of finding and applying for NIH money have changed underneath everyone. Here is how to rebuild your discovery workflow so nothing slips through.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleThe NIH Director's New Innovator Award (DP2, RFA-RM-27-002) closes August 17, 2026, offering roughly 30 Early Stage Investigators up to $475,000 in direct costs a year for five years — $2.375 million total — to pursue bold ideas without the preliminary data a standard R01 demands. Here is how the High-Risk, High-Reward program actually evaluates applications, who qualifies, and why the usual R01 instincts will sink you.
Read article